BR112016006582A2 - terapia combinada laquinimod para o tratamento da esclerose múltipla - Google Patents
terapia combinada laquinimod para o tratamento da esclerose múltiplaInfo
- Publication number
- BR112016006582A2 BR112016006582A2 BR112016006582A BR112016006582A BR112016006582A2 BR 112016006582 A2 BR112016006582 A2 BR 112016006582A2 BR 112016006582 A BR112016006582 A BR 112016006582A BR 112016006582 A BR112016006582 A BR 112016006582A BR 112016006582 A2 BR112016006582 A2 BR 112016006582A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- laquinimod
- multiple sclerosis
- combination therapy
- present
- Prior art date
Links
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004577 laquinimod Drugs 0.000 title abstract 4
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883698P | 2013-09-27 | 2013-09-27 | |
| PCT/US2014/057705 WO2015065628A2 (en) | 2013-09-27 | 2014-09-26 | Laquinimod combination therapy for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016006582A2 true BR112016006582A2 (pt) | 2017-08-01 |
Family
ID=52740749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016006582A BR112016006582A2 (pt) | 2013-09-27 | 2014-09-26 | terapia combinada laquinimod para o tratamento da esclerose múltipla |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20150094332A1 (enExample) |
| EP (1) | EP3049075A4 (enExample) |
| JP (1) | JP2016533323A (enExample) |
| KR (1) | KR20160085757A (enExample) |
| CN (1) | CN105848653A (enExample) |
| AR (1) | AR097792A1 (enExample) |
| AU (1) | AU2014342917A1 (enExample) |
| BR (1) | BR112016006582A2 (enExample) |
| CA (1) | CA2925493A1 (enExample) |
| EA (1) | EA201690673A1 (enExample) |
| IL (1) | IL244620A0 (enExample) |
| MX (1) | MX2016003763A (enExample) |
| SG (1) | SG11201602175VA (enExample) |
| TW (1) | TW201601722A (enExample) |
| UY (1) | UY35748A (enExample) |
| WO (1) | WO2015065628A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017514824A (ja) | 2014-04-29 | 2017-06-08 | テバ ファーマシューティカル インダストリーズ リミティド | 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| NZ573846A (en) * | 2006-06-12 | 2012-01-12 | Teva Pharma | Stable laquinimod preparations |
| US20100322900A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| EP2736335A4 (en) * | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
-
2014
- 2014-09-26 UY UY0001035748A patent/UY35748A/es not_active Application Discontinuation
- 2014-09-26 EA EA201690673A patent/EA201690673A1/ru unknown
- 2014-09-26 US US14/498,024 patent/US20150094332A1/en not_active Abandoned
- 2014-09-26 CA CA2925493A patent/CA2925493A1/en active Pending
- 2014-09-26 WO PCT/US2014/057705 patent/WO2015065628A2/en not_active Ceased
- 2014-09-26 KR KR1020167011039A patent/KR20160085757A/ko not_active Withdrawn
- 2014-09-26 EP EP14857795.0A patent/EP3049075A4/en not_active Withdrawn
- 2014-09-26 AU AU2014342917A patent/AU2014342917A1/en not_active Abandoned
- 2014-09-26 JP JP2016516547A patent/JP2016533323A/ja not_active Withdrawn
- 2014-09-26 BR BR112016006582A patent/BR112016006582A2/pt not_active IP Right Cessation
- 2014-09-26 SG SG11201602175VA patent/SG11201602175VA/en unknown
- 2014-09-26 CN CN201480053575.8A patent/CN105848653A/zh active Pending
- 2014-09-26 AR ARP140103582A patent/AR097792A1/es unknown
- 2014-09-26 MX MX2016003763A patent/MX2016003763A/es unknown
- 2014-09-26 TW TW103133660A patent/TW201601722A/zh unknown
-
2016
- 2016-03-15 IL IL244620A patent/IL244620A0/en unknown
- 2016-05-31 US US15/169,139 patent/US20160271094A1/en not_active Abandoned
-
2017
- 2017-07-06 US US15/643,214 patent/US20170304253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015065628A3 (en) | 2015-10-29 |
| US20160271094A1 (en) | 2016-09-22 |
| AU2014342917A1 (en) | 2016-04-21 |
| EP3049075A4 (en) | 2017-05-03 |
| UY35748A (es) | 2015-04-30 |
| US20170304253A1 (en) | 2017-10-26 |
| JP2016533323A (ja) | 2016-10-27 |
| EA201690673A1 (ru) | 2016-08-31 |
| EP3049075A2 (en) | 2016-08-03 |
| US20150094332A1 (en) | 2015-04-02 |
| CA2925493A1 (en) | 2015-05-07 |
| MX2016003763A (es) | 2016-10-28 |
| CN105848653A (zh) | 2016-08-10 |
| KR20160085757A (ko) | 2016-07-18 |
| WO2015065628A2 (en) | 2015-05-07 |
| TW201601722A (zh) | 2016-01-16 |
| IL244620A0 (en) | 2016-04-21 |
| AR097792A1 (es) | 2016-04-13 |
| SG11201602175VA (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| BR112015022538A2 (pt) | terapia de indução de rituximab seguida por terapia de acetato de glatirâmero | |
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| BR112014008731A2 (pt) | tratamento de esclerose múltipla com combinação de laquinimode e fingolimode | |
| BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
| MX2014001050A (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| NZ702087A (en) | Pharmaceutical compositions and treatment of mastitis | |
| BR112015026238A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| BR112015028516A2 (pt) | tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina | |
| BR112015006063A2 (pt) | compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 | |
| BR112016006582A2 (pt) | terapia combinada laquinimod para o tratamento da esclerose múltipla | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| BR112015028884A2 (pt) | tratamento ou prevenção de depressão utilizando mentol e/ou icilina | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| BR112015026484A2 (pt) | tratamento ou prevenção de dano neuronal não inflamatório de trauma cerebral e acidentes vasculares cerebrais usando mentol, linalool e/ou icilin | |
| BR112015004152A2 (pt) | combinação farmacêutica compreendendo um inibidor de fosfatidilinositol 3-quinase e um inibidor da aromatase | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2533 DE 23-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |